In the field of cancer research, understanding the cellular machinery involved in malignancy and drug resistance is crucial for developing effective therapies. Recently, the NRF2 signaling pathway has garnered attention for its role in driving metabolic reprogramming in cancer cells and protecting tumor cells from ROS-induced death. Additionally, NRF2 activation can alter the tumor microenvironment, potentially reducing inflammation. Despite extensive research, the intricate processes by which NRF2 influences metabolic pathways and how these pathways enable cancer cells to thrive in hostile environments remain inadequately understood.

This Research Topic aims to unravel the mechanisms behind NRF2-driven metabolic shifts that contribute to tumor growth and cancer drug resistance. By focusing on cellular responses, cross-talk between signaling pathways, and regulatory networks, this research seeks to provide a comprehensive understanding of how NRF2 engages in to facilitate survival and resistance mechanisms in cancer cells. Insights from this investigation could pave the way for novel therapeutic strategies aimed at improving cancer treatment.

To gather further insights in NRF2-driven metabolic shifts within the context of cell signaling, we welcome articles addressing, but not limited to, the following themes:

1. Cellular responses influenced by NRF2 signaling in cancer

2. Cross-talk between NRF2 pathways and other signaling networks

3. The role of signal transduction pathways in NRF2-mediated resistance

4. Molecular interactions and spatio-temporal dynamics of NRF2 signaling

5. NRF2 in the tumor microenvironment

6. Targeting NRF2 as potential therapeutic strategy in cancers

7. Techniques to study NRF2's involvement in signaling networks and cancer drug resistance

The section encourages submissions that provide mechanistic insights and experimental validation, aligning with broader implications for health and disease signaling. This multidisciplinary approach aims to communicate impactful discoveries in the field of cell signaling related to cancer drug resistance.

Pamela Lochead is an employee and shareholder of AstraZeneca. The remaining Topic Editors declare that the editorial work was conducted in the absence of any commercial or financial relationships.

Are you interested in contributing a manuscript to this Research Topic?

Decoding NRF2-Driven Metabolic Shifts in Cancer Drug Resistance